OCT 04, 2021 8:29 PM PDT

Guillain-Barre Syndrome After COVID-19 Infection

WRITTEN BY: Alexandria Bass

Researchers with the International GBS Outcome Study (IGOS) consortium investigated newly-diagnosed GBS patients from the beginning of the pandemic – January to March 2020 – to determine if there was an increased incidence of GBS related to SARS-CoV-2 infection. GBS cases have spiked in the past to the 1976 H1N1 swine flu vaccination and to the 2015 Zika virus pandemic.

Guillain-Barre is an autoimmune disease where progressive muscle weakness occurs as a result of immune destruction of nerves in the peripheral nervous system. There are different variants of GBS, with acute inflammatory demyelinating polyradiculoneuropathy (AIDP) being the most common form in the US. The AIDP variant involves sensory changes and symmetrical, rapidly progressive limb weakness that usually starts in the legs and moves upward, potentially paralyzing respiratory muscles. Other symptoms include numbness, tingling, and autonomic dysfunction that can cause cardiac arrhythmias and unstable blood pressures. 

Onset can occur after surgeries, medications, and gut and respiratory infections, such as infection with Campylobacter jejuni, Mycoplasma pneumoniae, Haemophilus influenzae, cytomegalovirus, and Epstein-Barr virus. Symptoms usually present around 3 weeks after infection and become most severe by 4 weeks from symptom onset. 

GBS is diagnosed through antibody testing for ganglioside antibodies, lumbar puncture for cerebrospinal examination, and electromyography and nerve conduction studies. Characteristic CSF findings include high protein levels with normal white blood cell counts.

Neurological conditions have been linked to COVID-19 infection. Other than the typical loss of sense of smell and taste, more serious neurological symptoms are strokes, changes in consciousness, and injury to the skeletal muscles. SARS-CoV-2 is thought to cause neurological symptoms by attaching to the ACE2 receptor present on nerve and muscle tissues.

In this international prospective observational cohort study, IGOS researchers did not detect an increase in GBS diagnosis during the first 4 months of the COVID-19 pandemic, suggesting GBS is not very likely to develop after COVID-19 infection. 

Of the 49 patients examined in the study, 8 had a confirmed and 3 had a probable COVID-19 infection before developing GBS symptoms, with no evidence of having had another recent infection that could explain the onset of GBS. COVID-19-related GBS cases were associated with a sensorimotor, demyelinating variant and with severe symptoms of GBS.
 

About the Author
BA in Psychology
Alexandria (Alex) is a freelance science writer with a passion for educating the public on health issues. Her other professional experience includes working as a speech-language pathologist in health care, a research assistant in a food science laboratory, and an English teaching assistant in Spain. In her spare time, Alex enjoys cycling, lap swimming, jogging, and reading.
You May Also Like
MAY 06, 2022
Technology
Smartphone App Screens for Neurological Conditions Using Pupil Scans
MAY 06, 2022
Smartphone App Screens for Neurological Conditions Using Pupil Scans
Neurological conditions can be devastating. Conditions like Alzheimer’s (which is becoming increasingly common as ...
MAY 06, 2022
Drug Discovery & Development
Scientists discover new methods of production for Sulphur-based medications
MAY 06, 2022
Scientists discover new methods of production for Sulphur-based medications
Modern medicine has drastically changed since humans discovered the first ancient treatment methods. Herbal remedies and ...
MAY 08, 2022
Technology
Detecting Cytokine Storm Through Sweat
MAY 08, 2022
Detecting Cytokine Storm Through Sweat
A cytokine storm is a severe immune system reaction where the body is flooded with cells and molecules (called cytokines ...
MAY 09, 2022
Technology
Taking a Break From Social Media Improves Mental Health
MAY 09, 2022
Taking a Break From Social Media Improves Mental Health
Nowadays, it seems like social media usage is a near ubiquitous part of our daily lives. In fact, the Pew Research Cente ...
MAY 09, 2022
Neuroscience
Can Gene Therapy Treat Psychiatric Disorders?
MAY 09, 2022
Can Gene Therapy Treat Psychiatric Disorders?
Using cutting-edge technologies, researchers have shown how mutations in a gene called Transcription Factor 4 (TCF4) can ...
MAY 19, 2022
Neuroscience
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
MAY 19, 2022
Daily Cranberry Consumption Boosts Cognitive Function, Reduces Cholesterol
Eating a cup of cranberries per day may improve memory, ward off dementia and reduce ‘bad’ cholesterol in th ...
Loading Comments...